$MRAI Cashflow Statement | Understand Stock

$MRAI

$3.03 +$0.40 (15.32%) Close

$MRAI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Depreciation and amortization
Loss on disposal of assets
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss on disposal of assets
Provision for credit losses
Loss on sale of receivables
Share-based compensation
Warrant expense
Shares issued to vendors in exchange for services
Amortization of right-of-use asset
Goodwill impairment charge
Impairment of goodwill and intangible assets
Loss/(gain) on sale of business unit
Loss on sale of business unit
Gain on forgiveness of other liability
Non-cash interest expense
Amortization of debt premium and debt issuance costs, net
Non-cash interest
Convertible note issued for professional services
Loss on debt extinguishment
Deferred taxes

Changes in operating assets and liabilities:
Accounts receivable and unbilled receivable
Prepaid expense and other assets
Other receivables
Security deposit
Accounts payable
Accounts payable - related party
Accrued expenses
Accrued fiduciary obligations
Operating lease liabilities
Due to related party
Other liabilities
Other asset
Net cash used in operating activities

Cash flows from investing activities:
Cash and restricted cash acquired as part of acquisition (Note 4)
Capitalization of software development costs
Purchases of intangible asset
Proceeds from disposal of property and equipment
Purchase of property and equipment
Proceeds from sale of business unit
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from initial public offering, net
Payments to seller for acquisition
Proceeds from issuance of common stock in a private offering, net
Proceeds from stock option exercises
Proceeds from issuance of convertible debentures
Proceeds from short-term loan
Payment for initial public offering costs
Proceeds from sale of future cash receipts on accounts receivable
Payments to buyer of receivables
Payments on convertible debentures
Payments of convertible debenture issuance costs
Net cash provided by financing activities

Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information
Conversion of convertible notes into common stock at the closing of the Acquisition, net
Conversion of convertible notes into common stock at the IPO
Office improvements included in accrued expenses
Common stock issued as part of the Acquisition
Cash paid for interest

Measurement period adjustment to goodwill
Long term liability incurred in connection with the acquisition of Maestro Health, LLC (Note 4)
Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheets
Cash and cash equivalents
Restricted cash

Comments